May 30, 2023
Aurora and MedReleaf Australia Launch new Medical Hashish Model


Canada’s main medical hashish supplier and Australia’s preeminent medical hashish provider to deliver three new premium strains to Australian sufferers

EDMONTON, AB, Feb. 22, 2023 /PRNewswire/ – Aurora Hashish Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian firm opening the world to hashish, and MedReleaf Australia at this time introduced the launch of CraftPlant, a brand new medical hashish model for sufferers within the Australian market.

The CraftPlant model consists of three new merchandise out there for medical doctors to prescribe – Greendae, Navana and HiVolt. All three are developed from ultra-premium cultivars and are THC-dominant with excessive percentages of terpenes. The cultivars had been developed by Occo, Aurora’s main science and genetics enterprise. The brand new vary is produced underneath strict EU-GMP licensed situations and might be out there in 10g containers.

“By means of our partnership with MedReleaf Australia, we’re proud to proceed to paved the way within the Australian market with the addition of recent and progressive merchandise for sufferers,” says Miguel Martin, CEO of Aurora Hashish. “As we construct on our strategic worldwide progress plans, Australia has confirmed to be a really promising and sustainable hashish market that we’re dedicated to.”

Aurora at the moment holds a ten% possession stake in MedReleaf Australia, a completely licensed, personal firm. Collectively, they supply Australian sufferers with a number of Aurora-branded merchandise, together with dried flower, oils and smooth gels.

Russell Harding, CEO of MedReleaf Australia says, “These new merchandise are the results of devoted exhausting work by the groups in each Canada and Australia, offering probably the most distinctive hashish cultivars out there within the Australian medical market. With CraftPlant, medical doctors now have 27 MedReleaf merchandise out there for his or her sufferers, offering a variety of attainable options for sufferers unable to acquire aid from their prior medicines or remedy, and produced underneath the strictest tips.”

For additional details about CraftPlant, medical doctors and well being care professionals can contact MedReleaf’s scientific help staff or go to their web site:

About Aurora

Aurora is opening the world to hashish, serving each the medical and shopper markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in world hashish, devoted to serving to folks enhance their lives. The Firm’s adult-use model portfolio consists of Aurora Drift, San Rafael ’71, Every day Particular, Whistler, Being and Greybeard, in addition to CBD manufacturers, Reliva and KG7. Medical hashish manufacturers embrace MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora additionally has a controlling curiosity in Bevo Farms Ltd., North America’s main provider of propagated agricultural crops. Pushed by science and innovation, and with a concentrate on high-quality hashish merchandise, Aurora’s manufacturers proceed to interrupt via as trade leaders within the medical, efficiency, wellness and grownup leisure markets wherever they’re launched. Study extra at and comply with us on Twitter and LinkedIn.

Aurora’s frequent shares commerce on the NASDAQ and TSX underneath the image “ACB”.

About MedReleaf Australia

MedReleaf Australia is a personal firm established in 2016. MedReleaf is licensed by the Australian Federal Authorities’s Workplace of Drug Management (ODC) to domesticate and manufacture medical hashish. MedReleaf additionally has licences to import, export and wholesale medical hashish. Its wholly owned subsidiary, MedReleaf NZ, additionally has a Medicinal Hashish Provide Licence issued by the New Zealand Ministry of Well being.

MedReleaf Australia is backed by greater than 50 years of pharmaceutical and healthcare experience, is pushed by Analysis and Improvement, and has an unique strategic partnership with Canada’s Aurora Hashish Enterprises.

An asset-lean distinct enterprise positioned to benefit from a quickly rising markets constructed to service the Australian and New Zealand medical industries together with medical doctors, pharmacists, and sufferers.

Ahead Trying Statements

This information launch consists of statements containing sure “forward-looking info” throughout the which means of relevant securities regulation (“forward-looking statements”). Ahead-looking statements are often characterised by phrases similar to “plan”, “proceed”, “count on”, “venture”, “intend”, “imagine”, “anticipate”, “estimate”, “might”, “will”, “potential”, “proposed” and different comparable phrases, or statements that sure occasions or situations “might” or “will” happen. Ahead-looking statements made on this information launch embrace, however usually are not restricted to, statements concerning the launch of recent and progressive merchandise to the Australian market via partnership with MedReleaf Australia, management within the Australian market via that partnership, and strategic worldwide progress plans, together with a dedication to the Australian market.                                                                                                    .  

These forward-looking statements are solely predictions. Ahead trying info or statements contained on this information launch have been developed primarily based on assumptions administration considers to be cheap.  Materials elements or assumptions concerned in growing forward-looking statements embrace, with out limitation, publicly out there info from governmental sources in addition to from market analysis and trade evaluation and on assumptions primarily based on information and data of this trade which the Firm believes to be cheap. Ahead-looking statements are topic to a wide range of dangers, uncertainties and different elements that administration believes to be related and cheap within the circumstances may trigger precise occasions, outcomes, stage of exercise, efficiency, prospects, alternatives or achievements to vary materially from these projected within the forward-looking statements. These dangers embrace, however usually are not restricted to, the flexibility to retain key personnel, the flexibility to proceed investing in infrastructure to help progress, the flexibility to acquire financing on acceptable phrases, the continued high quality of our merchandise, buyer expertise and retention, the event of third celebration authorities and non-government shopper  gross sales channels, administration’s estimates of shopper demand in Canada and in jurisdictions the place the Firm exports, expectations of future outcomes and bills, the chance of profitable integration of acquired enterprise and operations, administration’s estimation that SG&A will develop solely in proportion of income progress, the flexibility to broaden and keep distribution capabilities, the influence of competitors, the overall influence of economic market situations, the yield from hashish rising operations, product demand, modifications in costs of required commodities, competitors, and the chance for modifications in legal guidelines, guidelines, and rules within the trade, epidemics, pandemics or different public well being crises, together with the present outbreak of COVID-19, and different dangers, uncertainties and elements set out underneath the heading “Threat Elements” within the Firm’s annual info kind dated September 20, 2022 (the “AIF”) and filed with Canadian securities regulators out there on the Firm’s issuer profile on SEDAR at and filed with and out there on the SEC’s web site at  The Firm cautions that the record of dangers, uncertainties and different elements described within the AIF shouldn’t be exhaustive and different elements may additionally adversely have an effect on its outcomes. Readers are urged to contemplate the dangers, uncertainties and assumptions rigorously in evaluating the forward-looking statements and are cautioned to not place undue reliance on such info. The Firm is underneath no obligation, and expressly disclaims any intention or obligation, to replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as expressly required by relevant securities regulation. 

SOURCE Aurora Hashish Inc.

Aurora and MedReleaf Australia Launch new Medical Hashish Model